Ind-Swift Laboratories Q1 FY27 Results: Revenue Rs 191 Cr, PAT Rs 24 Cr and Key Highlights
- August 11, 2026
- Posted by: Neeraj Pandey
- Category: News
Ind-Swift Laboratories Q1 FY27 results declared August 10, 2026. Revenue Rs 191 Cr (+25.35% YoY). PAT Rs 24 Cr (+184.10% YoY). CMP Rs 237.24 (+3.87%).
Ind-Swift Laboratories Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +25.35% YoY to Rs 191 Cr from Rs 152 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 25 Cr (+940.37% YoY). PAT came in at Rs 24 Cr (+184.10% YoY), reflecting the key financial metrics of Ind-Swift Laboratories Q1 FY27 results.
Click Here – Get Free Investment Predictions
Ind-Swift Laboratories Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Ind-Swift Laboratories Revenue | 191 | 152 | +25.35% |
| Operating Profit | 25 | -3.00 | +940.37% |
| Net Profit (PAT) | 24 | 8.00 | +184.10% |
| Reporting Basis | Consolidated | ||
Ind-Swift Laboratories Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Ind-Swift Laboratories Q1 FY27 results reflect exceptional fundamentals. Revenue momentum were evident with the top line reaching Rs 191 Cr for the April to June 2026 quarter.
Operating profit expanded +940.37% YoY. PAT of Rs 24 Cr reflects +184.10% YoY movement. Investors tracking Ind-Swift Laboratories Q1 FY27 results will note these as key FY27 milestones.
Key Business Factors in Ind-Swift Laboratories Q1 FY27 Results
Revenue Expansion in Q1 FY27
Ind-Swift Laboratories Q1 FY27 results show revenue expanding +25.35% YoY to Rs 191 Cr from Rs 152 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.
Operating Margin Performance
Operating profit in Ind-Swift Laboratories Q1 FY27 results stood at Rs 25 Cr (+940.37% YoY). Better cost absorption and product mix improvement contributed to the operating performance.
PAT Trajectory and Profitability
PAT in Ind-Swift Laboratories Q1 FY27 results was Rs 24 Cr (+184.10% YoY), reflecting the company’s improving financial health.
Dividend Details
No dividend was declared alongside Ind-Swift Laboratories Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.
FY27 Outlook for Ind-Swift Laboratories
Ind-Swift Laboratories is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Ind-Swift Laboratories Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.
Ind-Swift Laboratories Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Ind-Swift Laboratories live price and get daily stock recommendations.
Ind-Swift Laboratories shares were trading higher at Rs 237.24 (+3.87%) on August 10, 2026, reflecting investor sentiment on Ind-Swift Laboratories Q1 FY27 results and the near-term sector outlook. The CMP of Rs 237.24 on the results date reflects broader sentiment toward the pharmaceuticals space.
Key Risks for Ind-Swift Laboratories
Sector-Specific Risks
USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.
Valuation and Earnings Risk
Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.
Operational and Financial Risk
Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.
Conclusion
Ind-Swift Laboratories Q1 FY27 results reflect exceptional performance with revenue at Rs 191 Cr and PAT at Rs 24 Cr on a Consolidated basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Ind-Swift Laboratories Q1 FY27 Results
When were Ind-Swift Laboratories Q1 FY27 results declared?
Ans. Ind-Swift Laboratories Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.
What was Ind-Swift Laboratories revenue in Q1 FY27?
Ans. Revenue in Ind-Swift Laboratories Q1 FY27 results was Rs 191 Cr, +25.35% YoY from Rs 152 Cr in Q1 FY26.
What was Ind-Swift Laboratories PAT in Q1 FY27?
Ans. Net profit in Ind-Swift Laboratories Q1 FY27 results was Rs 24 Cr (+184.10% YoY).
Did Ind-Swift Laboratories declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Ind-Swift Laboratories Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.
What is the FY27 outlook for Ind-Swift Laboratories?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.
How did Ind-Swift Laboratories stock react to Q1 FY27 results?
Ans. Ind-Swift Laboratories shares were higher at Rs 237.24 (+3.87%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.
